Latest News and Press Releases

High response rates: ORR of 54% and a CR rate of 38%Durable responses: ~25 months median duration of response Favourable safety profile: AEs predominantly low grade, tolerable, easily managed, and...

TORONTO and SAN DIEGO, Dec. 07, 2020 (GLOBE NEWSWIRE) -- Triphase Accelerator, a private drug development company dedicated to advancing novel compounds through clinical proof-of-concept, today...

Toronto, Ontario, and Somerset, N.J., April 01, 2019 (GLOBE NEWSWIRE) -- Triphase Accelerator Corporation, a company dedicated to acquiring and developing novel therapeutics for the treatment of...

TORONTO, ON, Jan. 29, 2019 (GLOBE NEWSWIRE) -- Triphase Accelerator, together with its majority shareholder FACIT, today announced a new strategic collaboration with Celgene for a first-in-class...

TORONTO and SOMERSET, N.J., Dec. 04, 2017 (GLOBE NEWSWIRE) -- Triphase Accelerator Corporation, a company dedicated to acquiring and developing novel therapeutics for the treatment of cancer, and...

TORONTO and SAN DIEGO, May 01, 2017 (GLOBE NEWSWIRE) -- Triphase Accelerator Corporation, a private drug development company dedicated to advancing novel compounds through Phase 2 proof-of-concept,...

TORONTO and SAN DIEGO, Dec. 21, 2016 (GLOBE NEWSWIRE) -- Triphase Accelerator Corporation, a private drug development company dedicated to advancing novel compounds through Phase 2 proof-of-concept,...

Marizomib is a novel brain-penetrant proteasome inhibitor in development for patients with glioblastoma and relapsed and/or refractory multiple myeloma TORONTO and SAN DIEGO, Nov. 18, 2016 (GLOBE...

Marizomib is a novel brain-penetrant proteasome inhibitor in development for patients with glioblastoma and relapsed and/or refractory multiple myeloma. TORONTO and SAN DIEGO, Nov. 17, 2016 (GLOBE...

SOMERSET, N.J. and LA JOLLA, Calif., Oct. 04, 2016 (GLOBE NEWSWIRE) -- Catalent, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and...